# Prostate Cancer Biomarker Enrichment and Treatment Selection

> **NCT03385655** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Canadian Cancer Trials Group** · enrollment: 200 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Adavosertib
- **DRUG:** Savolitinib
- **DRUG:** Darolutamide
- **DRUG:** CFI-400945
- **DRUG:** Ipatasertib
- **DRUG:** Durvalumab and Tremelimumab
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT03385655
- **Lead sponsor:** Canadian Cancer Trials Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-08-01
- **Primary completion:** 2024-10-07
- **Final completion:** 2025-12-31
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2025-08-21

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03385655

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03385655, "Prostate Cancer Biomarker Enrichment and Treatment Selection". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT03385655. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*